SCPH - scpharmaceuticals.com Debt to Book Capitalization Ratio

Graphic logo of scPharmaceuticals (SCPH)

This price chart for scPharmaceuticals Inc. (SCPH) reflects the price action of an asset whose stability depends on the success of a single infusion system, creating a risk of single-product dependency. The current indicator is 0.00. scPharmaceuticals Inc. (SCPH) develops wearable devices for furosemide administration, enabling cardiology patients to receive treatment at home. Therapy safety is ensured through a calibrated transport chain for specific medications.

SCPH (scPharmaceuticals) Debt to Book Value history from 07/04/2022 to 10/18/2025
Core merchandise of scPharmaceuticals

scPharmaceuticals Inc. investments in the greening of chemical production and closed-loop water systems require significant capital, making debt load control critical. By analyzing the dynamics of the debt-to-capitalization ratio, an investor assesses the proportion of borrowed funds within the net asset structure to determine the business's ability to maintain stability and avoid financial collapse during periods of market volatility.

Competitors of scPharmaceuticals Inc.

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value TECX|Tonix Pharmaceuticals (TNXP) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio SXTC (sxtchina.com)|Debt to Book Capitalization Ratio EPRX|Debts to Net Assets BioHarvest Sciences, Inc. BHST|EXOZ: Debts to Book Capitalization|ORMP: Debt to Book Value|Debt to Book Capitalization Ratio enterabio.com (ENTX)|ipatherapeutics.com (HYFT) - Debts to Book Capitalization Ratio|ABVC - Debts to Book Capitalization|Debt to Net Assets Ratio Cumberland Pharmaceuticals Inc|Debts to Book Capitalization QNTM|Debts to Book Capitalization FGEN (FibroGen Corporation)|Debt to Book Capitalization Ratio Telomir Pharmaceuticals|Rani Therapeutics Holdings - Debt to Net Assets Ratio|SNYR: Debt to Book Capitalization Ratio|RLYB - Debt to Book Value|LEXX: Debts to Book Capitalization|Pulmatrix Corporation (PULM) - Debts to Book Capitalization|Debts to Book Capitalization PTHL|Debt to Book Value Aptorum|Lyra Therapeutics - Debts to Book Capitalization|Debts to Book Value Impact BioMedical, Inc. IBO|Debt to Book Value TNFA (TNF Pharmaceuticals, Inc.)|YCBD - Debts to Book Capitalization|Debt to Book Value PainReform Ltd. PRFX|CYTO - Debt to Book Capital|Lipella Pharmaceuticals, Inc. - Debts to Book Capitalization|OptiNose Inc (OPTN) - Debts to Net Assets|Debts to Book Capitalization PIRS|Debt to Book Value Procaps Group Corp|Debts to Book Capitalization PTPI|Debts to Book Capitalization QLI (qlsyy.net)|Debt to Book Capitalization Ratio ACELYRIN SLRN|TFF Pharmaceuticals Inc. - Debt to Book Capitalization Ratio